Brian Adams
General Counsel presso RELAY THERAPEUTICS, INC.
Patrimonio netto: 3 M $ in data 31/03/2024
Profilo
Brian R.
Adams is currently the Secretary & Chief Legal Officer at Relay Therapeutics, Inc. He previously worked as the Secretary, Senior Vice President & General Counsel at Keryx Biopharmaceuticals, Inc. from 2014 to 2018, and as the General Counsel at Algeta ASA from 2012 to 2014.
Mr. Adams completed his undergraduate degree at Harvard University and his graduate degree at Columbus School of Law.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
RELAY THERAPEUTICS, INC.
0.25% | 29/04/2024 | 325 767 ( 0.25% ) | 3 M $ | 31/03/2024 |
Posizioni attive di Brian Adams
| Società | Posizione | Inizio |
|---|---|---|
| RELAY THERAPEUTICS, INC. | General Counsel | 01/03/2018 |
Precedenti posizioni note di Brian Adams
| Società | Posizione | Fine |
|---|---|---|
| KERYX BIOPHARMACEUTICALS | General Counsel | 13/03/2018 |
| ALGETA ASA | General Counsel | 01/03/2014 |
Formazione di Brian Adams
| Harvard University | Undergraduate Degree |
| Columbus School of Law | Graduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| RELAY THERAPEUTICS, INC. | Health Technology |
| Aziende private | 2 |
|---|---|
Keryx Biopharmaceuticals, Inc.
 Keryx Biopharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Keryx Biopharmaceuticals, Inc. engaged in the manufacture, development, and commercialization of medicines for use in treating human diseases. The company was founded in August 1, 2002 and was headquartered in Cambridge, MA. | Health Technology |
Algeta ASA
 Algeta ASA Pharmaceuticals: MajorHealth Technology Algeta ASA is engaged in the development of products for the treatment of cancer. The company focuses on the development of anti-cancer drugs, and its research and development of compounds focuses on the various applications of a few base compounds. Its products, Alpharadin and Thorium-227, are being developed for treatment of skeletal metastases originating from prostate and breast cancer. The company was founded by Roy H. Larsen and Øyvind Sverre Bruland in 1997 and is headquartered in Oslo, Norway. | Health Technology |
- Borsa valori
- Insiders
- Brian Adams
